# Harpoon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/harpoon-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.harpoontx.com
- Total disclosed funding: $110M
- Latest round: Series C (Nov 9, 2018)
- Investors on record: 9

## About

Based in California, US, and founded in 2015 by founder Patrick Baeuerle, Harpoon Therapeutics, Inc. operates as a biopharmaceutical company providing clinical-stage immuno-oncology for cancer and other diseases. In March 2024, Merck & Co., Inc. agreed to acquire Harpoon Therapeutics, Inc. from MPM BioImpact, Arix Bioscience, New Leaf Venture Partners, and many more for USD 680 million at USD 23 per share.  

Harpoon Therapeutics, Inc. developed immunotherapies using T-cell recruiting antibodies called TriTAC (tri-specific t-cell activating construct), designed to fight solid tumors and hematologic malignancies to treat patients with cancer and other rare diseases. The company offers ProTriTAC platform, which is a prodrug concept, supports to create a therapeutic T cell engager that remains inactive until it reaches the tumor.

## Funding rounds

- Series C, Nov 9, 2018, $70M — OrbiMed Advisors, New Leaf Venture Partners, Lilly Asia Ventures, MPM BioImpact, Ridgeback Capital Management, Arix Bioscience, Taiho Ventures, Timefolio Capital, Cormorant Capital
- Series B, May 24, 2017, $25M — New Leaf Venture Partners, MPM BioImpact, Arix Bioscience, Taiho Ventures
- Series A, Apr 1, 2016, $15M — MPM BioImpact

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B, Series C
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- Ridgeback Capital Management — Series C
- Timefolio Capital — Series C
- Cormorant Capital — Series C